Followers | 149 |
Posts | 9,339 |
Boards Moderated | 7 |
Alias Born | 03/29/2017 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah, good peeps here. NP bro.
Per CEO dilution will be at the utmost minimal. Any common shares will be tied directly 2 management.
They have intentions on OTCQB followed by NASDAQ. They want no dilution 2 protect PPS... I was skeptical @ first but after conversations with CEO and IR, they are dead serious.
Yup rock. Steady climb without PR.. with PR.. this should be fun.
LOL nice brother. Good man.
Damn right Beer. Good 2 hear. Get a real PR out, good times ahead $TVOG
$TVOG is pleased to announce deal closure. Press and filings have been cleared by compliance and are set for release. #Bitumen #Infrastructure #Asphalt
Nice brother.. Showtime soon. $TVOG
lol
As of the date of this filing, November 25, 2017, TongRen Liu is the owner of 75,000,000 shares of Series A Preferred stock issued by the Company. For the reported period, Mr. Hirji was the owner of 75,000,000 shares of Series A Preferred stock issued by the Company. The transfer of the 75,000,000 shares of Series A Preferred stock issued by the Company occurred in 2017.
My date wins.
Mentioning other boards is off topic but sorry 4 saying that. You have point in that connection.
New direction here obviously so we shall see .
Last filing shows he signed it with this but supplement before that said he was president. I DO NOT KNOW.
/s/ Wayne Anderson Name: Wayne Anderson Title: Director
Such a heavy word haha TY.
Yeah. Good justice is coming 2 these peeps. Ivory towers crashing down on them haha. Good 2 see ya ww.
That should be put on the other board, here shows preferred owned by new owner as recent filings show. I guess you can say he is president here but it was passed around musical chair like before these filings.. NEW DIRECTION imo.
Keep posting here on topic, which is AMHD.
As of the date of this filing, November 25, 2017, TongRen Liu is the owner of 75,000,000 shares of Series A Preferred stock issued by the Company. For the reported period, Mr. Hirji was the owner of 75,000,000 shares of Series A Preferred stock issued by the Company. The transfer of the 75,000,000 shares of Series A Preferred stock issued by the Company occurred in 2017.
Again, I think being overly aggressive when it is just starting puts it in an unfair light.
Gotta check filings, I wish my brain worked that way. I live on west coast if that gives you any hints lol.
I'm all 4 shining lights on scams with facts not just fingers.
What has come out so far shows change of hands with all intentions on starting fresh. That is what anyone would want if they purchased a shell/pinky.. If it follows same route, Ill be first 2 say what a dud.
Disagree Fuzzy. Company is changing hands. RS is wiping slate. Calling it a scam when new filings, company PR and RS are coming isn't fair.
AS is not changed by RS, just OS.
Crazy numbers Jett. Infrastructure plan will be golden 4 $TVOG
lol nice 1. He is onto his next blockbuster, 2 busy I bet .
You know it my man. Peeps have been accumulating this 4 last week or so.. $TVOG
This is gonna fly after RS.. Float under 10 million.. Peeps are selling lol.
On December 1, 2017, the Company's Board of Directors voted and approved to change the Company's name to HLK Biotec Holding Group, Inc., reverse split the Company's common stock on a 1:1000 ratio and change the authorized Common stock to 500 million shares. The proposed corporate actions were approved by shareholder(s) holding seventy percent (70%) of the shareholder vote.
On December 4, 2017, the Company filed an Amendment to its Articles of Incorporation to effectively complete all three actions approved by the Board, and filed an Issuer CompanyRelated Action Notification form with the Financial Industry Regulatory Authority.
http://www.otcmarkets.com/financialReportViewer?symbol=AMHD&id=183996
lol I have a hard time remembering yesterday but I recall that haha. you nailed it bro if they indeed do 1000. I thought 100 would work but agreed wit ya on RS needed.
Why in the holy hockey sticks would they buy a shell with bloated OS and not reverse it.. Paid all that money 2 go current. Best 4 everyone, back 1 step forward multiple.
Volume is in overdrive. Might see 4s fall if peeps lessen up.
I agree brother. Huge news Pepsi.
I2R will work on protocol development, medical writing, and regulatory consulting for Rich as it plans to move forward with clinical trials in Hodgkin's Lymphoma (HL). Subsequently, the Company intends to have I2R assist in preparing the protocol for submission to the Food and Drug Administration (FDA).
Love seeing "submission to the FDA thrown around."
Gotta get this party started peeps. Early bird always gets the worm.
Good start 2 day. $TVOG
Nice information Check. Gonna sticky it brother.
haha nice bro. I believe it will all come together perfectly 4 us here. Good peeps here.
Nice factual info sunshine. $TVOG gonna bring the heat IMO.
Totally agree serious.. This trades so tight, when it breaks itll just cheetah.
If they wanted 2 start converting more notes, they would run it up around .001 IMO.
Regardless, it is something they are transparent about.. Pays the bills.
Colonial wanted 2 charge me on first attempt haha.
Wouldn't surprise me if they dumped.. Buy volume does show 2 to 1 but some large sells. Don't know why they would hit bid, waste a PR run.
lol once a week limit nice.. I just was asked for $10 last week by TA 2 release OS numbers lol.. Nice little business if one of them setup an online portal 2 release SS info.
Sorry for your lack of _______
lol you guys deserve something really special
I doubt it. System they have is awesome. Bones of it is worth mucho IMO. They just had way 2 much money out the door. News shows they might be trying 2 fix that .
Connecture Inc. (CNXR) filed a Form 8K - Director, Officer or Compensation Filing - with the U.S Securities and Exchange Commission on November 28, 2017.
On November 28, 2017, the Board of Directors (the "Board") of Connecture, Inc. (the "Company"), approved a transition plan pursuant to which Brian D. Lindstrom would be hired and appointed Chief Financial Officer and Corporate Secretary and Vincent E. Estrada, the Company's prior Chief Financial Officer and Corporate Secretary, would transition to a new role within the Company as Executive Vice President of Corporate Development, each effective December 4, 2017.
Prior to joining the Company, Mr. Lindstrom, age 46, served as Chief Operating Officer of Datica Health, Inc., a provider of HIPAA compliant, cloud-based infrastructure for developers across healthcare, from December 2016 through November 2017. Previously, Mr. Lindstrom served as the Chief Financial Officer of Influence Health, Inc., a developer of clinical and digital marketing software for healthcare providers, from May 2013 through November 2016, and as Corporate Controller for Epic Systems, Inc., a provider of inpatient and ambulatory enterprise healthcare management software, from May 2007 through April 2013. Mr. Lindstrom is a CPA, holds a B.S. in accounting from Bradley University, M.S. from Purdue University and Advanced Management Program from University of Chicago.
Mr. Lindstrom's annual base salary will be $275,000, he will have an annual target bonus of 50% of his annual base salary. In connection with his appointment, the Company will grant Mr. Lindstrom restricted stock units representing 300,000 shares of the Company's common stock.
In connection with the appointment of Mr. Lindstrom as Chief Financial Officer as of December 4, 2017, Mr. Estrada will assume the role of Executive Vice President of Corporate Development. In connection with his new position, Mr. Estrada entered into a letter agreement, pursuant to which he has agreed to reduce his annual salary to $85,000 and retain a target bonus of 50% of his annual base salary, each effective January 1, 2018. Additionally, Mr. Estrada agreed to amend his employment agreement to provide that if he is terminated before January 1, 2019, the base salary used for purposes of determining his severance payments thereunder will be $300,000 and if he is terminated after January 1, 2019, his base salary for purposes of determining his severance payments will be his then-current base salary.
$RCHA huge news out
Rich Pharmaceuticals Retains Experienced Contact Research Organization to Assist with Clinical Trials
10:35 am ET December 5, 2017 (Globe Newswire) Print
Rich Pharmaceuticals, Inc. (OTC PINK: RCHA), a biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology, today announced that it has retained IND 2 Results, LLC, (I2R) Atlanta Georgia, to serve as its Contact Research Organization (CRO).
I2R will work on protocol development, medical writing, and regulatory consulting for Rich as it plans to move forward with clinical trials in Hodgkin's Lymphoma (HL). Subsequently, the Company intends to have I2R assist in preparing the protocol for submission to the Food and Drug Administration (FDA).
In addition, I2R is assisting the Company in amending the Acute Myelocytic Leukemia (AML) protocol in preparation for the Submission Package to a major U.S. clinical site soon-to-be-named, and I2R will also prepare submission packages for the clinical site's Institutional Review Board (IRB). In cooperation with the clinical site, and subject to the receipt of adequate additional funding, Rich Pharmaceuticals plans to conduct a study for the treatment of AML in refractory patients in Phase I/II trial. AML is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Because the incidence increases with age, it is expected that incidence will rise as population ages.
"I2R has a strong track record of success in conducting complicated clinical trials. Its multi-disciplinary team of experienced clinical trial professionals will work with Rich Pharmaceuticals as we move forward with our innovative treatment for lymphoma and leukemia," said Ben Chang, Rich Pharmaceuticals CEO. "We believe that getting a talented CRO team on board is an important step for our future."
http://www.ind2results.com/